Daclizumab (Zinbryta▼) in multiple sclerosis: Review patients for liver function currently on treatment

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Daclizumab (Zinbryta▼) 150 mg solution for injection is authorised for adults with relapsing forms of multiple sclerosis. Initiate daclizumab in restricted groups of patients who have highly active relapsing multiple sclerosis that has failed to respond to at least one disease-modifying therapy or severe relapsing multiple sclerosis unsuitable for treatment with other disease-modifying therapies.

Treatment with daclizumab is contraindicated in patients with pre-existing hepatic disease or hepatic impairment. Treatment initiation is not recommended in patients with alanine transaminase or aspartate aminotransferase 2 or more times the upper limit of normal.Treatment initiation is not recommended in patients with a history of concurrent autoimmune conditions (except for multiple sclerosis). Caution should be used when concomitantly administering medicinal products of known hepatotoxic potential, including non-prescription products and herbal supplements.

Wide review of daclizumab started after the death from liver injury (fulminant liver failure) of a patient involved in an ongoing observational study, as well as 4 cases of serious liver injury. The risk of liver damage with daclizumab was already known at time of its approval in the EU. Several measures are already in place to manage this risk, including the requirement to monitor liver function regular...

Recommended for you

  • Drug Updates
  • 1 comment

Daclizumab (Zinbryta▼) in multiple sclerosis: Review patients for liver function currently on treatment

Read more
  • Drug Updates
  • 1 comment

Nivolumab (Opdivo▼), pembrolizumab (Keytruda▼): Risk of graft rejection

Read more
  • Drug Updates
  • 1 comment

Bendamustine (Levact): Increased mortality when used in combination treatment outside the approved indications

Read more
  • Drug Updates
  • 1 comment

Denosumab (Prolia, Xgeva▼): Risk of osteonecrosis of jaw and external auditory canal

Read more
  • Drug Updates
  • 1 comment

Brimonidine gel (Mirvaso): Risk of cardiovascular events if applied to damaged skin

Read more
  • Drug Updates
  • 1 comment

Yellow Card Scheme Website: Report any side effects or safety concerns with e-cigarettes and e-liquids

Read more
  • Drug Updates
  • 1 comment

Restrictions to manage the risk for misuse of pseudoephedrine and ephedrine to be continued

Read more
  • Drug Updates
  • 1 comment

Finasteride 1 mg (Propecia): Reports of depression and suicidal thoughts in men

Read more
  • Drug Updates
  • 1 comment

Valproate (Epilim▼, Depakote▼): High risk of neurodevelopmental disability and birth defects

Read more
  • Drug Updates
  • 1 comment

Ponatinib (Iclusig▼): Risk of vascular arterial occlusion is dose-dependent

Read more
  • Drug Updates
  • 1 comment

Multiple sclerosis: Rebound syndrome after stopping fingolimod (Gilenya▼) or switching therapy

Read more
  • Drug Updates
  • 1 comment

Canagliflozin (Invokana▼): Increased risk of lower limb amputation

Read more
  • Drug Updates
  • no comment

Pilot website to report adverse reactions of psychoactive substances

Read more
  • Drug Updates
  • 1 comment

Idelalisib (Zydelig▼): updated safety information on risk of infection

Read more
  • Drug Updates
  • 1 comment

Levonorgestrel-containing emergency contraceptives: interaction with hepatic enzyme inducers

Read more
  • Drug Updates
  • 1 comment

Posaconazole (Noxafil): tablets and oral suspension not interchangable

Read more
  • Drug Updates
  • 1 comment

Lonsurf ▼(trifluridine/tipiracil) approved for colorectal cancer chemotherapy

Read more
  • Drug Updates
  • 1 comment

Riociguat (Adempas) contraindicated in pulmonary hypertension associated with idiopathic interstitial pneumonias

Read more
  • Drug Updates
  • 1 comment

Suspected fatal drug interaction between citalopram and cocaine

Read more
  • Drug Updates
  • 1 comment

N-acetylcysteine interference with Siemens assays: false-low test results

Read more
  • Drug Updates
  • 1 comment

Rare reports of calciphylaxis in patients taking warfarin

Read more
  • Drug Updates
  • 1 comment

Epclusa (sofosbuvir/velpatasvir) approved for treatment of chronic HCV infection

Read more
  • Drug Updates
  • 1 comment

Duavive (conjugated oestrogens/ bazedoxifene) approved for treatment of menopausal symptoms

Read more
  • Drug Updates
  • 1 comment

Hyoscine butylbromide: serious adverse effects in cardiac patients

Read more
  • Drug Updates
  • no comment

Drug safety alert: Risk of diabetic ketoacidosis with SGLT2 inhibitors

Read more
  • Drug Updates
  • no comment

Drug safety alert: Risks of PML, basal-cell carcinoma, and opportunistic infections associated with Fingolimod (Gilenya▼)

Read more
  • Drug Updates
  • 1 comment

Drug safety alert: Minimizing cardiac side effects associated with concomitant use of apomorphine and domperidone

Read more
  • Drug Updates
  • 1 comment

Drug safety update: Risk of progressive multifocal leukoencephalopathy with dimethyl fumarate (Tecfidera)

Read more
  • Drug Updates
  • 1 comment

Apremilast (Otezla▼): risk of psychiatric symptoms

Read more
  • Drug Updates
  • 1 comment

Direct-acting antivirals for chronic HCV (interferon-free): risk of hepatitis B reactivation

Read more